Dishman Carbogen Amcis Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4nbyl9ee6m1wouj1yu68s1zg.pdf

Key Takeaways


Regulatory Reset: Bavla & India CRAMS

Arpit Vyas: "The customers who know what we need are not just happy, but they're extremely calm because they were also very anxious for all the companies in India getting such import alerts, especially at the time when the business was shifting from China to India."

French Facility: The Drag That Is Now a Tailwind

Pascal Villemagne: "It was not entirely expected. Although we were using German provider for those lines, well known with a high reputation. But still, this is the start-up of greenfield facility. So it's not something that comes out of the blue just like this and you just press the button and everything works."

One-Off Costs: FY24 Clean-Up

ItemAmount (INR crores)Nature
French operations one-off46Machine malfunction and trial batch failure resolution
Non-routine maintenance/refurbishment22One-time overhaul of reactors and piping at an overseas site
Employee cost inflation catch-up31Incremental salary correction across the group
SaaS IT project (D365 France)9Digital transformation implementation
Soil reclamation provision4Netherlands site, to bring soil to manufacturing quality
Forex loss (notional)10Balance of Q3 notional loss not reversed in Q4

Segment Performance

SegmentTrendCommentary
Carbogen Amcis CRAMS▼ Missed budgetRevenue shifted out of Q4 due to French machine failure and trial batch failures; cholesterol and vitamin D analogues grew 50%+ YoY in Q4.
India CRAMS▲ RecoveringFull year down ~12% on EDQM restrictions, but Q4 grew 16% as Bavla clearance unlocked commercial supply.
India Quats & Generics▼ DeclinedRevenue fell from INR49 crores to INR29 crores in Q4 on agrochemical slowdown and a tough FY23 base that included deferred FY22 orders.
Swiss entity▬ SteadyGuided to 8–10% revenue growth in FY25; houses ~500 scientists doing early-stage development work that feeds the commercial pipeline.
U.K. entity▲ Low-base reboundGuided to 40–50% growth in FY25 after a weak base; one major customer who did not manufacture in FY24 has now returned.
Netherlands▬ Margin focusRevenue can be increased easily but the priority is profitability; raw material costs (wool grease) expected to decline, improving margins.

Balance Sheet & Capital Allocation


Growth Levers Beyond the Fix

Arpit Vyas: "One analogy, which is at -- in our case is that of going through chemotherapy to get rid of the cancer. After we get rid of the cancer, the chemo will leave -- we'll have some weakness initially. But then you will be able to run faster in the wind."

Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growthMinimum 10–12% growthFY25
Consolidated EBITDA margin18–20% (including French losses); 20% barring translation impactFY25
India CRAMS revenueINR350 croresFY25
India CRAMS revenueINR400 croresFY26
India CRAMS revenueINR450–500 croresFY27
French entity EBITDA lossINR35–40 crores (down from ~INR100 crores in FY24)FY25
French entity breakevenEBITDA breakevenFY26
PAT profitabilityTurn positiveFY26
Free cash flowGenerate positive free cash flow; CFO of INR400–500 croresFY25
Net debtKeep reducing over next 2–3 years as FCF is generatedFY25–FY27
Swiss entity revenue growth8–10%FY25
U.K. entity revenue growth40–50% (low base)FY25
CRAMS revenue growth14–15%FY25
CapexNo major outlay beyond routine maintenance and one water plantFY25 onward

Key Metrics

MetricQ4 FY24
Consolidated revenue₹654 cr, +6% YoY from ₹618 cr in Q4 FY23
Consolidated revenue (full year)₹2,616 cr, +8.5% YoY from ₹2,413 cr in FY23
EBITDA (adjusted for one-offs)~₹100 cr, vs ₹83 cr in Q4 FY23
EBITDA (full year, adjusted)~₹409 cr, vs ~₹414 cr in FY23
Cash profit (full year)₹303 cr, vs ₹326 cr in FY23
Cash generated from operations (full year)~₹400 cr
Carbogen Amcis CRAMS revenue₹449 cr, +~3% YoY
Carbogen Amcis CRAMS revenue (full year)₹1,953 cr, +15% YoY
Carbogen Amcis CRAMS EBITDA margin15.5%, vs 16% in Q4 FY23
Cholesterol and vitamin D analogues revenue₹91 cr, +>50% YoY from ₹60 cr in Q4 FY23
Cholesterol and vitamin D analogues EBITDA margin~25%, vs 13% in Q4 FY23
India CRAMS revenue₹85 cr, +16% YoY from ₹73 cr in Q4 FY23
India CRAMS EBITDA margin5.2%, vs ~2% in Q4 FY23
India quats and generics revenue₹29 cr, vs ₹49 cr in Q4 FY23
French entity negative EBITDA₹47 cr; full year ₹97 cr
French entity confirmed orders as of March 31€0.95 cr; highly expected from RFPs €0.7 cr; planned RFPs ~€9 cr
Consolidated EBITDA margin guidance for FY2518% to 20%
Consolidated revenue growth guidance for FY2510% to 12%
Capex guidance for FY25₹2.5 cr to ₹3 cr (maintenance capex ~₹1.8 cr)
Total advances from customers as of March 31, 2024₹634 cr
Capital work in progress₹500 cr, down from ₹996 cr in previous year
Net leverage ratio at Carbogen Amcis Holding4.8x, vs covenant of 4x
Economic equity ratio at Carbogen Amcis Holding33%, vs covenant of 40%
Net debt at Carbogen Amcis Holding~CHF10 cr
One-time maintenance and refurbishment expenditure₹22 cr
One-time employee cost inflation adjustment₹31 cr
SaaS IT project cost (one-off)₹9 cr
Provision for soil reclamation in Netherlands₹4 cr
Notional forex loss for full year₹9.69 cr
Goodwill write-off impact per annum~₹45 cr